Constellation Pharmaceuticals
Constellation Pharmaceuticals is a clinical-stage oncology biopharmaceutical company developing small-molecule drugs targeting selective regulators of epigenetic function for cancer treatment, based in Cambridge, MA and listed on NASDAQ as CNST.
- Company typePrivate
- Founded2008
- HeadquartersCambridge, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Constellation Pharmaceuticals does
Constellation Pharmaceuticals is a clinical-stage oncology biopharmaceutical company founded in 2008 and headquartered in Cambridge, Massachusetts. The company develops small-molecule drugs in the field of epigenetics, focusing on selective regulators of epigenetic function, which represent a mechanistically novel class of targeted cancer therapies. Its scientific platform was built by founding scientists David Allis, Danny Reinberg, and Yang Shi, three of the most recognized researchers in chromatin biology and epigenetic regulation, lending the company deep scientific credibility in its core therapeutic area.
The company's pipeline is centered on selective modulators of epigenetic targets, with development activity spanning hematologic malignancies and solid tumors. Business activity is funded by repeated equity financings — over $750 million raised across more than thirteen rounds between 2008 and 2019 — with consistent backing from founder-affiliated investors The Column Group, Third Rock Ventures, and Venrock, plus later-stage participation from Fidelity, Hillhouse, Deerfield, Cormorant, Casdin, OrbiMed, and Bain Capital Life Sciences. A 2012 strategic collaboration with Genentech provided both capital and validation, and the company maintains a public listing on NASDAQ under ticker CNST.
Revenue mechanics are characteristic of a pre-commercial biotech: there are no marketed products disclosed in the available sources, and any inflows would be limited to collaboration milestones rather than product sales. The organization has 101-250 employees, consistent with a mid-cap clinical development company building out commercial capabilities in advance of potential product launches.
Constellation Pharmaceuticals firmographics
Firmographics- Name
- Constellation Pharmaceuticals
- Website
- https://constellationpharma.com
- Company type
- Private
- Founded year
- 2008
- Headcount range
- 101–250 employees
- Short description
- Constellation Pharmaceuticals is a clinical-stage oncology biopharmaceutical company developing small-molecule drugs targeting selective regulators of epigenetic function for cancer treatment, based in Cambridge, MA and listed on NASDAQ as CNST.
- Ownership category
- akta.pro rank
Constellation Pharmaceuticals industry classification
Industry- Product category
- Epigenetic Oncology Pharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Oncology Specialty Pharmaceuticals (HLAIACAA)
Keywords
Where Constellation Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Markets served
Constellation Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Constellation Pharmaceuticals product offering
Product offeringCore offering
Constellation Pharmaceuticals develops pharmaceutical drugs in the field of epigenetics, focusing on selective regulators of epigenetic function for cancer indications. The company discovers and advances small-molecule therapeutic candidates targeting chromatin and gene-expression regulatory mechanisms implicated in oncology.
Differentiator
Problem solved
Functional benefit
Companies that use Constellation Pharmaceuticals
Customer profileIdeal customer profiles1 record
Constellation Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Constellation Pharmaceuticals partnerships and signals
Strategic signalRecent moves6 records
Expansion highlights4 records
Constellation Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Syndax Pharmaceuticals: Clinical-stage oncology company developing EZH2 and menin-MLL inhibitors. Shares Constellation's focus on selective regulators of epigenetic function in oncology, including HDAC and related chromatin-modifying targets.
- Epizyme: Directly comparable epigenetic-focused oncology company with the FDA-approved EZH2 inhibitor Tazverik. Competes with Constellation in the same epigenetic target space and patient populations, particularly in hematologic malignancies and solid tumors.
- Forma Therapeutics: Clinical-stage biopharmaceutical company developing small molecules targeting rare hematologic diseases and cancers, including epigenetic targets such as IDH1/2. Directly comparable in scale and pipeline focus.
- Oryzon Genomics: Clinical-stage epigenetics company developing LSD1 and other chromatin-modifying inhibitors for oncology and CNS indications. Comparable as a focused epigenetic-mechanism drug developer.
Broad incumbents
- Roche / Genentech: Strategic investor in Constellation (led the 2012 $95M round) and a major oncology pharma with internal epigenetic research programs. Comparable as a partner, competitor, and potential acquirer.
- Bristol-Myers Squibb: Global oncology pharma with multiple BET and epigenetic programs in development and the commercial scale to compete or acquire in this space. Represents the dominant large-pharma competitive threat in epigenetic oncology.
- AbbVie: Diversified biopharma with oncology programs including epigenetic targets. Comparable as a large-pharma acquirer and competitor in the selective chromatin regulator space.
- Constellation Pharmaceuticals (acquired by MorphoSys context — using Celgene as comparable): Large oncology specialty pharma with deep interest in epigenetic mechanisms. Broad portfolio across hematology and solid tumors with the resources and commercial reach to absorb pipeline assets of Constellation's size.
Emerging players
- Foghorn Therapeutics: Clinical-stage biotech developing a new class of medicines targeting the chromatin regulatory system. Highly comparable mechanistically to Constellation's focus on selective regulators of epigenetic function.
- Prelude Therapeutics: Clinical-stage precision oncology company developing a pipeline that includes PRMT5 and other chromatin-targeting agents. Comparable as an emerging epigenetic-focused oncology developer.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks4 records
Key highlights5 records
Customer concentration
Constellation Pharmaceuticals social profiles
Digital presenceConstellation Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Constellation Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles5 records
Constellation Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds14 records
Investors22 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Constellation Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Constellation Pharmaceuticals
What does Constellation Pharmaceuticals do?
Constellation Pharmaceuticals develops pharmaceutical drugs in the field of epigenetics, focusing on selective regulators of epigenetic function for cancer indications. The company discovers and advances small-molecule therapeutic candidates targeting chromatin and gene-expression regulatory mechanisms implicated in oncology.
When was Constellation Pharmaceuticals founded?
Constellation Pharmaceuticals was founded in 2008. It employs 101 to 250 people.
Where is Constellation Pharmaceuticals based?
Constellation Pharmaceuticals is headquartered in Cambridge, United States, in the North America region.
Who are Constellation Pharmaceuticals's main competitors?
Direct peers on record are Syndax Pharmaceuticals, Epizyme, Forma Therapeutics and Oryzon Genomics. Broad incumbents are Roche / Genentech, Bristol-Myers Squibb, AbbVie and Constellation Pharmaceuticals (acquired by MorphoSys context — using Celgene as comparable). Emerging players are Foghorn Therapeutics and Prelude Therapeutics.
Does Constellation Pharmaceuticals have an API?
No public API is recorded for Constellation Pharmaceuticals.
What industry is Constellation Pharmaceuticals in?
Constellation Pharmaceuticals's product category is Epigenetic Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIACAA, Oncology Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.